When was 3Brain founded?

3Brain was founded in 2011 and raised its 1st funding round 10 years after it was founded.

Where is 3Brain located?

3Brain is headquartered in Wadenswil, Switzerland.

How many employees does 3Brain have?

As of Aug 31, 2026, the latest employee count at 3Brain is 58.

Is 3Brain a funded company?

3Brain is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round on Jan 09, 2021.

When was the latest funding round of 3Brain?

3Brain's latest funding was a $***** Grant (prize money) round on Jan 09, 2021, with participation from 1 investor.

Where does 3Brain rank among its competitors?

3Brain ranks 68th amongst 112 active competitors, of which 34 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of 3Brain?

3Brain's top competitors include Seer, Tango Therapeutics and Maze Therapeutics. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

3Brain - 2026 Company Profile, Team, Funding & Competitors

Company Details

3Brain sells large scale high resolution MEA recording platforms and CMOS-MEA biochips. 3Brain's patented core technology spans the field of large scale high resolution microelectrode array systems for in-vitro electrophysiology. Their key competences are focused on CMOS integrated bio-sensor arrays for recording extracellular signals from electrogenic cells, networks and tissues, such as in-vitro neuronal networks, brain slices and cardiac tissue preparations. 3Brain’s technology is the result of several years of development and of experience on CMOS-MEA chips. The initial concept has been devised in the PhD thesis of Luca Berdondini (group of Prof. Milena Koudelka-Hep and Prof. Nico F. De Rooij, SAMLAB-IMT, University of Neuchâtel) and successively brought to life with the first prototype developed during an European project (project IDEA, FP6-NEST framework, 2005-2008) coordinated by SAMLAB, EPFL, Switzerland and strongly supported by DIBRIS (group of Prof. Sergio Martinoia, DIBRIS, University of Genova, Italy). The company is currently supported by CSEM and by the Fondazione Istituto Italiano di Tecnologia (IIT - team of Dr. Berdondini).

Website: www.3brain.com/
Social
Email ID: *****@3brain.com

Key Metrics

Founded Year

2011

Location

Wadenswil, Switzerland

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Jan 09, 2021, $*****

Investors

Swiss ICT Investor Club & 2 more

Ranked

68^th among 112 active competitors

Employee Count

58 as on Aug 31, 2026

Similar Companies

Seer & 142 more

View 3Brain's full profile

3Brain has raised funding over 1 round. Its latest funding round was a Grant (prize money) round on Jan 09, 2021 for $*****. 1 investor participated in its latest round. 3Brain has 3 institutional investors.

Here is the list of recent funding rounds of 3Brain:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 09, 2021	8213281	Grant (prize money)	3421188	8059096	5311784	7223087

Access funding benchmarks and valuations. Sign up today!

View details of 3Brain's funding rounds and investors

The founders of 3Brain are Alessandro Maccione and Mauro Gandolfo.

Here are the details of 3Brain's key team members:

Alessandro Maccione: Co-Founder & CSO of 3Brain.
Mauro Gandolfo: Co-Founder & CEO of 3Brain.

View details of 3Brain's Founder profiles and Board Members

3Brain's employee count trend

3Brain has 58 employees as of Aug 26. Here is 3Brain's employee count trend over the years:

Uncover 3Brain's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 3Brain include Seer, Tango Therapeutics and Maze Therapeutics. Here is the list of Top 10 competitors of 3Brain, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Fidelity Investments & 15 others	72/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
3rd	Maze Therapeutics 2018, Redwood City (United States), Public	Developer of genetic bio-markers in neurological, metabolic, and renal diseases	$496M	Matrix Capital Management, Frazier Life Sciences ... & 21 others	66/100
4th	Metabolon 2000, Morrisville (United States), Series H	Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine	$166M	Sevin Rosen, Syngenta Group Ventures & 17 others	66/100
5th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, New Enterprise Associates ... & 3 others	64/100
6th	Wobble Genomics 2020, Edinburgh (United Kingdom), Series A	Provider of a platform for discovery of nucleic acid biomarkers	$12.5M	Mercia, Eos Advisory & 35 others	62/100
7th	Oxford Biodynamics 2007, Oxford (United Kingdom), Public	Developer of personalized diagnostics by identifying biomarkers through epigenetics	$11M	Armistice Capital, Oxford University Innovation ... & 1 others	56/100
8th	Proteomics International 2001, Perth (Australia), Public	Medical technology company at the forefront of predictive diagnostics and bio-analytical services	-	MTPConnect, NorthStar Impact	55/100
9th	Denovo Biopharma 2013, San Diego (United States), Series D	Developer of genomic biomarker discovery platform	$172M	Guangzhou Yuexiu Industrial Investment Fund Management, CICC ... & 12 others	55/100
10th	Valirx 2000, London (United Kingdom), Public	Developer of novel technologies and products in oncology therapeutics and diagnostics	-	-	53/100
68th	3Brain 2011, Wadenswil (Switzerland), Funding Raised	High resolution MicroElectrode Array (#MEA) platform to study #Brain and #retinal disorders ( #Alzheimer's and #Parkinson's diseases, #Retinitis#Pigmentosa)	-	Swiss ICT Investor Club, Europa & 1 others	27/100